Genomic Biomarker Market Analysis & Forecast: 2026-2033

Genomic Biomarker Market Size and Share Analysis- Growth Trends and Forecasts (2026-2033)

The Genomic Biomarker Market size is estimated to expand at a CAGR of 9.5% with USD 6.9 Bn in 2026 and is expected to reach USD 13.1 Bn by 2033. Increasing use of precision medicine, rising prevalence of cancer and genetic disorders, expanding demand for companion diagnostics, and developments in next generation sequencing (NGS) technology are the main drivers of market expansion. According to the National Center for Biotechnology Information (NCBI) 2025. Cancer treatment is also progressing towards personalized medicine approaches, where therapies are developed based on the specific molecular features of a patient’s tumor, potentially leading to improved clinical outcomes and fewer side effects.

Key Takeaways

• Oncology segment is projected to hold the largest market share with 46.8% in 2026. The segment’s rise is attributed to the growing acceptance of genomic biomarkers for precision oncology, companion diagnostics, early cancer detection, treatment response monitoring, and targeted therapy selection. According to American Cancer Society estimates that there will be 2,041,910 new cancer cases and 618,120 cancer deaths in the U.S. in 2025. This emphasizes the increasing importance of genomic biomarker-based diagnoses and customized treatment techniques.
• Diagnostic & research laboratories segment to lead with 49.2% in 2026. The segment is growing due to the rising volume of next generation sequencing (NGS), molecular diagnostics, genomic profiling, biomarker validation studies and translational research activities. According to the U.S. Centers for Disease Control and Prevention (CDC) Next-Generation Sequencing (NGS) Quality Initiative is developing validated, standardized validation, quality management, and laboratory best practices to support the growing use of NGS in clinical and public health laboratories, with an emphasis on increasing the use of genomic sequencing in routine diagnostics.
• The Genomic Biomarker Market in North America is projected to lead with an estimated market share of 41.8% in 2026. The leadership of the region is driven by significant investments in precision medicine, broad adoption of next-generation sequencing (NGS), a mature molecular diagnostics infrastructure, supportive reimbursement policies and the existence of major biotechnology and pharmaceutical businesses. According to the National Institutes of Health, the All of Us Research Program has engaged more than one million individuals to build one of the largest and most diverse biological datasets in the world to accelerate precision medicine and genomic research.

Segmental Insights 

To learn more about this report, Request Free Sample

Why is Oncology Acquiring the Largest Share?

By indication, oncology segment is predicted to have the highest proportion of the Genomic Biomarker Market in 2026, estimated at 46.8%. The segment growth is attributed to the growing utilization of genomic biomarkers in precision oncology, companion diagnostics, early cancer detection, treatment response monitoring, and targeted therapy selection. Increasing availability of biomarker-guided medicines and extensive genetic profiling is helping clinicians individualize treatment plans and enhance patient outcomes across a range of cancer types.

According to the U.S. Food and Drug Administration (FDA) has cleared or approved a number of companion diagnostic devices that can help identify patients most likely to benefit from specific targeted medicines, with the bulk of these uses in oncology. This is similar to the rising clinical application of genetic biomarkers for cancer diagnosis and treatment selection.

In September 2025, Guardant Health announced that the U.S. Food and Drug Administration (FDA) approved Guardant360 CDx as a companion diagnostic for Eli Lilly’s Inluriyo (imlunestrant) to detect patients with ESR1-mutated advanced or metastatic breast cancer. This broadens the clinical utility of liquid biopsy-based genetic indicators in precision oncology and helps guide the choice of tailored treatments.

Why are Diagnostic & Research Laboratories Holding the Largest Market Share? 

To learn more about this report, Request Free Sample

The Diagnostic & Research Laboratories segment is anticipated to hold the biggest Genomic Biomarker Market share of 49.2% in 2026. The segment’s rise is due to the rising volumes of next-generation sequencing (NGS), molecular diagnostics, genomic profiling, biomarker validation studies, and translational research activities. The growing need for complete genomic profiling, along with the emergence of precision medicine, is bolstering the importance of specialized diagnostic laboratories.

According to the International Quality Network for Pathology (IQN Path), 119 of the 127 labs (93.7%) that participated in the peer-reviewed survey have NGS technology, while 117 labs (92.1%) use the NGS technology for tumor genomic profiling in a routine manner. These findings show that NGS is extensively utilized by molecular pathology labs.

In May 2025, Illumina has introduced their new clinical oncology portfolio that included increased availability of TruSight Oncology (TSO) Comprehensive and the addition of Pillar oncoReveal CDx on the MiSeq Dx System. Both systems provide an opportunity for hospitals and reference laboratories to conduct comprehensive genomic profiling and companion diagnostics on-site.

Market Drivers

Expansion of Cancer Genomic Testing and Companion Diagnostics is Fueling Market Growth

The genomic biomarker market is being driven significantly by the increasing usage of cancer genomic testing and companion diagnostics. Hospitals, cancer centers and diagnostic labs are turning to comprehensive genetic profiling more and more to discover molecular abnormalities, guide targeted medicines and enhance patient outcomes. The demand for genomic biomarkers is growing exponentially with the rise of biomarker-guided clinical trials and precision oncology initiatives throughout the healthcare ecosystem.

According to the American Society of Clinical Oncology (ASCO) has recommended the use of molecular biomarker testing as standard-of-care for several types of cancers such as non-small cell lung cancer (NSCLC), breast cancer, colorectal cancer, ovarian cancer and prostate cancer to aid in targeted treatment decisions and improve clinical outcomes.

Current Events and Their Impact on the Genomic Biomarker Market

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Genomic Biomarker Market Trends

• Increased application of comprehensive genomic profiling (CGP) and next-generation sequencing (NGS) is increasing the application of biomarkers in the clinical setting. Hospitals and laboratories are increasingly using multigene panel testing to identify actionable gene mutations, as well as directing personalized treatments. According to ESMO (European Society for Medical Oncology), complete genomic profiling is becoming increasingly recommended in cases where cancer patients’ advanced diseases have a good chance of being influenced by their test results.
• The progress in AI and bioinformatics is contributing significantly towards the acceleration of genomic data interpretation and biomarker discovery. The AI-based analytics technology is aiding in the identification of clinically significant genetic variants, as well as helping in the development of precision medicine and treatment. The 2025 research study published in the Nature Medicine journal proves that the use of AI in genomic analysis is highly beneficial for precision medicine adoption.
• National and international genomics projects are fast-tracking the discovery and implementation of biomarkers in the clinical setting. National governments and scientific organizations are investing huge amounts of funds in population-level genome sequencing, which is done to improve preventive medicine and personalized medicine. According to Genomics England, there have been more than 100,000 whole genomes sequenced through the 100,000 Genomes Project, and thus a large national database has been created for studying rare diseases and cancer.

Regional Insights 

To learn more about this report, Request Free Sample

North America Dominates Owing to Strong Precision Medicine Infrastructure and Advanced Genomic Research

North America region is expected to account for 41.8% share of the Genomic Biomarker Market by 2026. The region’s growth is fueled by well-developed precision medicine programs, widespread adoption of next-generation sequencing (NGS), advanced molecular diagnostics infrastructure, favorable reimbursement policies and large investments in genomic research by government agencies and private organizations. The presence of renowned biotechnology businesses, pharmaceutical manufacturers, and academic research organizations further fosters the discovery and commercialization of genetic biomarkers.

According to the U.S. Food and Drug Administration (FDA) said companion diagnostics are critical to the safe and effective use of targeted medicines and are increasingly being incorporated into oncology treatment pathways in the U.S. healthcare system.

In June 2025, Guardant Health received FDA Breakthrough Device Designation for its Shield Multi-Cancer Detection (MCD) blood test, designed for early cancer screening using genomic and epigenomic biomarkers.

Asia Pacific Genomic Biomarker Market Trends

The Asia Pacific region is projected to experience the highest growth rate in the Genomic Biomarker Market throughout the forecast period. This growth is due to various factors such as the rise in precision medicine initiatives, growing investments in genomic sequencing programs, high prevalence of cancers, improvements in health care facilities, and high adoption of molecular diagnostic procedures in countries including China, Japan, South Korea, India, and Australia.

In April 2026, Deloitte announced the launch of the Asia Pacific Health Institute which will focus on promoting healthcare transformation in the region by use of technology, artificial intelligence diagnostics, and precision medicine.

Strong Precision Medicine Ecosystem and Federal Genomics Programs Driving Market Growth in the United States

The U.S. is a leading player in the Genomic Biomarker Market, with a robust precision medicine infrastructure, widespread use of next-generation sequencing (NGS) and significant federal funding for genomic research and clinical translation. Biomarker-based diagnostics are quickly being integrated into oncology, rare illnesses and pharmacogenomics within the country's healthcare environment.

According to the U.S. Food and Drug Administration (FDA), patients with many types of cancer are often tested at the molecular level as part of their clinical care. This enables doctors to select targeted therapies based on the genomic profile of the tumor. In this manner, precision medicine approaches enhance treatment outcomes.

In June 2026, the U.S. Fish and Wildlife Service (U.S. government agency) announced a cooperation with Colossal Biosciences to build a large-scale Genomic and Cellular BioVault. The effort will preserve living cells, reproductive organs and genomic DNA from nearly 2,300 endangered species listed under the U.S. Endangered Species Act.

Government-Led Genomics Expansion and Large-Scale Precision Medicine Programs Driving Rapid Growth in China

China is emerging as one of the fastest expanding markets for genetic biomarkers, fueled by robust government investment in precision medicine, massive population genomics initiatives, and the rapid rollout of next-generation sequencing (NGS) infrastructure in hospitals and research institutes.

According to the Chinese Academy of Sciences (CAS) has financed a series of national genome sequencing programs. The goal of these programs is to establish large-scale population genomic databases to facilitate biomarker discovery and illness risk prediction.

In February 2026, the Indian Institute of Technology Madras (IIT-M) launched the Bharat Cancer Genome Atlas (BCGA), a large-scale cancer genome database covering leukaemia, colorectal and pancreatic cancers, to improve identification of population-specific genomic biomarkers and precision oncology applications.

Who are the Major Companies in Genomic Biomarker Industry

Some of the major key players in Genomic Biomarker Market are Thermo Fisher Scientific, F. Hoffmann-La Roche AG, Liquid Genomics, Inc., AROS Applied Biotechnology A/S, Myriad Genetics, Inc., QIAGEN, Eurofins Scientific, Genomic Health, Bio-Rad Laboratories, Inc., Epigenomics AG, and Aepodia.

Key News

• In October 2025, Thermo Fisher Scientific introduced a new microarray data analysis solution designed to improve efficiency, automation, and sustainability in genomic research workflows. The solution enhances processing of large-scale genomic and biomarker datasets by reducing manual intervention and improving data interpretation speed in NGS-adjacent and microarray-based genomic studies.
• In March 2024, King’s College London launched a new state-of-the-art genomics facility (“King’s Genomics”), formed through the merger of two major research centres to strengthen capabilities in genomic sequencing, biomarker discovery, and precision medicine research.

Market Report Scope

Analyst Opinion

• Liquid biopsy is emerging as a major shift in genomic biomarker adoption, enabling non-invasive cancer detection and real-time disease monitoring. According to the U.S. National Cancer Institute (NCI), liquid biopsy technologies using circulating tumor DNA (ctDNA) are increasingly being evaluated for early cancer detection and treatment monitoring, especially in lung and colorectal cancers, improving clinical decision-making without invasive tissue sampling.
• Expansion of biobanking and population-scale genomic databases is accelerating biomarker discovery pipelines. The UK Biobank reports biological and genetic data from over 500,000 participants, enabling large-scale association studies that help identify disease-linked genomic variants and biomarkers for precision medicine applications.
• Regulatory acceleration for genomic-based diagnostics is improving commercialization pathways. The U.S. FDA Breakthrough Devices Program has designated hundreds of diagnostic innovations, including genomic and molecular tests, to speed up access to clinically impactful biomarker-based technologies for unmet medical needs.
• Rare disease diagnosis is becoming a key growth driver for genomic biomarker utilization. The NIH estimates that more than 7,000 rare diseases exist, affecting over 300 million people globally, many of which require genomic sequencing and biomarker-based testing for accurate diagnosis due to lack of conventional clinical markers.

Market Segmentation

• By Indication (Revenue, USD Bn, 2021-2033)
  • Oncology
  • Cardiovascular diseases
  • Neurological diseases
  • Others
• By End User (Revenue, USD Bn, 2021-2033)
  • Hospitals
  • Diagnostic & Research Laboratories
  • Others
• By Region (Revenue, USD Bn, 2021-2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa

Sources

Primary Research Interviews

• Clinical geneticists
• Molecular pathologists
• Oncologists and hematologists
• Hospital laboratory directors
• Diagnostic laboratory managers
• Biotechnology and pharmaceutical R&D heads
• Key opinion leaders (KOLs) in genomics and precision medicine

Databases

• National Institutes of Health (NIH)
• National Center for Biotechnology Information (NCBI)
• U.S. Food and Drug Administration (FDA)
• Centers for Disease Control and Prevention (CDC)
• World Health Organization (WHO)
• International Agency for Research on Cancer (IARC)
• Organisation for Economic Co-operation and Development (OECD)
• Genomics England (UK national genomics program)

Magazines

• GEN – Genetic Engineering & Biotechnology News
• Nature Biotechnology News
• Bio-IT World
• Clinical OMICs
• GenomeWeb

Journals

• Nature Genetics
• Nature Medicine
• The Lancet Oncology
• Journal of Molecular Diagnostics
• Genome Medicin
• American Journal of Human Genetics

Newspapers

• The New York Times
• The Guardian
• The Wall Street Journal
• Financial Times
• Reuters Health

Associations

• American Society of Human Genetics (ASHG)
• American College of Medical Genetics and Genomics (ACMG)
• European Society of Human Genetics (ESHG)
• American Society of Clinical Oncology (ASCO)
• Clinical Pharmacogenetics Implementation Consortium (CPIC)
• International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

Public Domain Sources

• Company Annual Reports and Investor Presentations (Thermo Fisher, Roche, QIAGEN, Illumina, etc.)
• Government Health Ministry Publications (USA, UK, EU, India, China)
• ClinicalTrials.gov
• WHO Global Health Observatory Data Repository
• FDA Approved Companion Diagnostic Device List
• NIH Genomic Data Sharing (GDS) Policy Resources

Proprietary Elements

• CMI Data Analytics Tool
• Proprietary CMI Repository (10+ years historical dataset)